Correlation Between Lyra Therapeutics and Recursion Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Lyra Therapeutics and Recursion Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lyra Therapeutics and Recursion Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lyra Therapeutics and Recursion Pharmaceuticals, you can compare the effects of market volatilities on Lyra Therapeutics and Recursion Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lyra Therapeutics with a short position of Recursion Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lyra Therapeutics and Recursion Pharmaceuticals.

Diversification Opportunities for Lyra Therapeutics and Recursion Pharmaceuticals

0.14
  Correlation Coefficient

Average diversification

The 3 months correlation between Lyra and Recursion is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Lyra Therapeutics and Recursion Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Recursion Pharmaceuticals and Lyra Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lyra Therapeutics are associated (or correlated) with Recursion Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Recursion Pharmaceuticals has no effect on the direction of Lyra Therapeutics i.e., Lyra Therapeutics and Recursion Pharmaceuticals go up and down completely randomly.

Pair Corralation between Lyra Therapeutics and Recursion Pharmaceuticals

Given the investment horizon of 90 days Lyra Therapeutics is expected to under-perform the Recursion Pharmaceuticals. In addition to that, Lyra Therapeutics is 1.11 times more volatile than Recursion Pharmaceuticals. It trades about -0.05 of its total potential returns per unit of risk. Recursion Pharmaceuticals is currently generating about 0.03 per unit of volatility. If you would invest  717.00  in Recursion Pharmaceuticals on September 26, 2024 and sell it today you would earn a total of  7.00  from holding Recursion Pharmaceuticals or generate 0.98% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Lyra Therapeutics  vs.  Recursion Pharmaceuticals

 Performance 
       Timeline  
Lyra Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Lyra Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Recursion Pharmaceuticals 

Risk-Adjusted Performance

2 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Recursion Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, Recursion Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Lyra Therapeutics and Recursion Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Lyra Therapeutics and Recursion Pharmaceuticals

The main advantage of trading using opposite Lyra Therapeutics and Recursion Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lyra Therapeutics position performs unexpectedly, Recursion Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Recursion Pharmaceuticals will offset losses from the drop in Recursion Pharmaceuticals' long position.
The idea behind Lyra Therapeutics and Recursion Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Complementary Tools

Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Fundamental Analysis
View fundamental data based on most recent published financial statements